BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, Cao Y, Li C, Xiao Y, Gu C, Zhang S, Li D, Zhang Y, Zhang T, Zhou J, Huang L. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood 2020;136:516-9. [PMID: 32291456 DOI: 10.1182/blood.2020004907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Uhlving HH, Harritshøj LH, Christensen VB, Ifversen M. Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection. Pediatr Blood Cancer 2021;:e29208. [PMID: 34227723 DOI: 10.1002/pbc.29208] [Reference Citation Analysis]
2 Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.042] [Reference Citation Analysis]
3 Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy. Front Immunol 2021;12:751754. [PMID: 34691067 DOI: 10.3389/fimmu.2021.751754] [Reference Citation Analysis]
4 Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021;32:34-48. [PMID: 33098993 DOI: 10.1016/j.annonc.2020.10.478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
5 Reagan PM, Neelapu SS. How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. JCO 2021;39:456-66. [DOI: 10.1200/jco.20.01616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lai P, Chen X, Qin L, Jiang Z, Luo C, Huang X, Wu S, Ling W, Wang Y, Wang J, Deng C, Huang L, Zeng L, Lu Z, Zhong L, Liao P, Li M, Chen D, Geng S, Wu P, Tang Z, Pei D, Du X, Li P, Weng J. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia 2020;34:2790-3. [PMID: 32632097 DOI: 10.1038/s41375-020-0952-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang J, Shang Z, Wang J, Xu J, Li W, Guan Y, Yang L, Zhang W, Shen K, Zhang M, Wang J, Chen L, Li Q, He C, Wang N, Huang L, Xiao Y, Xiao M, Zhou J. MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy. J Immunother Cancer 2021;9:e002029. [PMID: 34078654 DOI: 10.1136/jitc-2020-002029] [Reference Citation Analysis]
8 Chinese Society of Lymphoma, Chinese Anti-cancer Association., Chinese Society of Hematology, Chinese Medical Association. [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:441-6. [PMID: 34384148 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wang D, Mao X, Que Y, Xu M, Cheng Y, Huang L, Wang J, Xiao Y, Wang W, Hu G, Zhang S, Zhang T, Li C, Zhou J. Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. Blood Cancer J 2021;11:168. [PMID: 34663791 DOI: 10.1038/s41408-021-00563-8] [Reference Citation Analysis]